Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming E...
May 18 2017 - 7:30AM
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage
biopharmaceutical company developing novel therapeutics for
oncology indications of unmet medical need, announced today that
SL-401 Stage 1 and 2 data from its ongoing pivotal Phase 2 trial in
blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been
accepted for poster presentation at the 2017 European Hematology
Association (EHA) Annual Meeting, to be held June 22-25, 2017 in
Madrid, Spain.
Details on the presentation is as follows:
|
SL-401 - BPDCN Presentation |
Title: |
|
Ongoing Phase 2
Clinical Trial Of SL-401 In Patients With Blastic Plasmacytoid
Dendritic Cell Neoplasm (BPDCN): Stage 1 And Stage 2 Results |
Presenter: |
|
Naveen Pemmaraju, MD;
MD Anderson Cancer Center |
Abstract: |
|
P191 |
Session: |
|
Acute myeloid leukemia
– Clinical 1 |
Date/Time: |
|
Friday, June 23 –
5:15-6:45 PM CET |
Location: |
|
Hall 7 – Poster
Area |
|
|
|
Stemline remains on track to provide an update on BPDCN patients
enrolled in Stage 3 of the Phase 2 pivotal trial in the second half
of this year.
About Stemline Therapeutics Stemline
Therapeutics, Inc. is a clinical stage biopharmaceutical company
developing novel therapeutics for oncology indications of unmet
medical need. A Phase 2 pivotal trial with SL-401, a targeted
therapy directed to the interleukin-3 receptor (CD123), has
completed enrollment of patients with blastic plasmacytoid
dendritic cell neoplasm (BPDCN) in the Stage 3 cohort, and patients
continue to be followed. SL-401 has been granted Breakthrough
Therapy Designation (BTD) for the treatment of BPDCN. Additional
Phase 1/2 trials with SL-401 are enrolling patients with other
malignancies including high-risk myeloproliferative neoplasms (MPN)
and acute myeloid leukemia (AML) in remission with minimal residual
disease (MRD). A Phase 1/2 trial of SL-401 in combination with
pomalidomide is enrolling patients with relapsed/refractory
multiple myeloma. A Phase 1 dose escalation trial with SL-801, a
novel oral small molecule reversible inhibitor of XPO1, is
enrolling patients with advanced solid tumors. A Phase 2 trial with
SL-701, an immunotherapy designed to activate the immune system to
attack tumors, has completed dosing and patients with second-line
glioblastoma are being followed for survival.
Forward-Looking Statements Some of the
statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The factors that could cause our
actual results to differ materially include: the success and timing
of our clinical trials and preclinical studies for our product
candidates, including site initiation, institutional review board
approval, scientific review committee approval, patient accrual,
safety, tolerability and efficacy data observed, and input from
regulatory authorities including the risk that the FDA or other
ex-U.S. national drug authority ultimately does not approve any of
our product candidates; our plans to develop and commercialize our
product candidates; market acceptance of our products;
reimbursement available for our products; our available cash and
investments; our ability to obtain and maintain intellectual
property protection for our product candidates; our ability to
manufacture; the performance of third-party manufacturers, clinical
research organizations, clinical trial sponsors and clinical trial
investigators; and other risk factors identified from time to time
in our reports filed with the Securities and Exchange Commission.
Any forward-looking statements set forth in this press release
speak only as of the date of this press release. We do not intend
to update any of these forward-looking statements to reflect events
or circumstances that occur after the date hereof.
Contact
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: investorrelations@stemline.com
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Apr 2023 to Apr 2024